CN113631168B - Gpr35调节剂 - Google Patents

Gpr35调节剂 Download PDF

Info

Publication number
CN113631168B
CN113631168B CN202080024043.7A CN202080024043A CN113631168B CN 113631168 B CN113631168 B CN 113631168B CN 202080024043 A CN202080024043 A CN 202080024043A CN 113631168 B CN113631168 B CN 113631168B
Authority
CN
China
Prior art keywords
alkyl
branched
straight
pharmaceutically acceptable
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080024043.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113631168A (zh
Inventor
罗伯特·希古奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometheus Biosciences Inc
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of CN113631168A publication Critical patent/CN113631168A/zh
Application granted granted Critical
Publication of CN113631168B publication Critical patent/CN113631168B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080024043.7A 2019-01-24 2020-01-23 Gpr35调节剂 Active CN113631168B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US62/796,459 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US62/873,703 2019-07-12
US201962928223P 2019-10-30 2019-10-30
US62/928,223 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (2)

Publication Number Publication Date
CN113631168A CN113631168A (zh) 2021-11-09
CN113631168B true CN113631168B (zh) 2024-11-19

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024043.7A Active CN113631168B (zh) 2019-01-24 2020-01-23 Gpr35调节剂

Country Status (13)

Country Link
US (2) US11053251B2 (enExample)
EP (1) EP3914256B1 (enExample)
JP (1) JP7588077B2 (enExample)
KR (1) KR102863894B1 (enExample)
CN (1) CN113631168B (enExample)
AU (1) AU2020210930B2 (enExample)
BR (1) BR112021014566A2 (enExample)
CA (1) CA3127786A1 (enExample)
IL (1) IL285074B2 (enExample)
MA (1) MA54825A (enExample)
MX (1) MX2021008941A (enExample)
TW (1) TWI845600B (enExample)
WO (1) WO2020154492A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
WO2022020617A1 (en) * 2020-07-23 2022-01-27 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987160A (en) * 1970-12-15 1976-10-19 May & Baker Limited Pharmaceutical compositions comprising azapurinones useful in treating allergic respiratory disorders
WO2004035584A1 (fr) * 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
CA2558721A1 (en) * 2004-02-27 2005-09-15 Pfizer Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
WO2012167053A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
US20150273088A1 (en) 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
US10519373B2 (en) 2014-06-29 2019-12-31 Profile Products, L.L.C. Bark and wood fiber growing medium
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
TW202014217A (zh) * 2018-04-27 2020-04-16 美國錫安山醫學中心 標靶gpr35以治療發炎性腸病症的組合物及方法
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
WO2020163713A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
MA54903A (fr) 2019-02-08 2021-12-15 Cedars Sinai Medical Center Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
WO2021108694A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
WO2022020617A1 (en) 2020-07-23 2022-01-27 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
JP2023551602A (ja) 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987160A (en) * 1970-12-15 1976-10-19 May & Baker Limited Pharmaceutical compositions comprising azapurinones useful in treating allergic respiratory disorders
WO2004035584A1 (fr) * 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antiallergic Activity of 2-Phenyl-8-azapurin-6-ones;B. J. Broughton et al.;《Journal of Medicinal Chemistry》;第18卷(第11期);第1117-1122页 *
GPR35 as a novel therapeutic target;A. E. MacKenzie et al.;《Frontier in endocrinology》;第2卷;第1-10页 *

Also Published As

Publication number Publication date
MA54825A (fr) 2021-12-01
CN113631168A (zh) 2021-11-09
JP7588077B2 (ja) 2024-11-21
AU2020210930B2 (en) 2025-08-14
KR102863894B1 (ko) 2025-09-23
TW202043234A (zh) 2020-12-01
EP3914256A4 (en) 2022-09-28
EP3914256B1 (en) 2024-05-29
IL285074B1 (en) 2024-08-01
EP3914256A1 (en) 2021-12-01
JP2022518523A (ja) 2022-03-15
US11053251B2 (en) 2021-07-06
US11773101B2 (en) 2023-10-03
CA3127786A1 (en) 2020-07-30
AU2020210930A1 (en) 2021-09-09
IL285074B2 (en) 2024-12-01
IL285074A (en) 2021-09-30
US20210380590A1 (en) 2021-12-09
KR20210119485A (ko) 2021-10-05
MX2021008941A (es) 2021-10-13
US20200239476A1 (en) 2020-07-30
TWI845600B (zh) 2024-06-21
WO2020154492A1 (en) 2020-07-30
BR112021014566A2 (pt) 2022-01-04

Similar Documents

Publication Publication Date Title
CA2903293C (en) Heterocyclic compounds and uses thereof
JP5806417B2 (ja) Ｍｇａｔ２阻害剤としてのアリールジヒドロピリジノンおよびピペリジノン
US11773101B2 (en) GPR35 modulators
JP2025532670A (ja) Ｐｃｓｋ９阻害剤及びその使用方法
IL307559A (en) Deuterated dihydroorotate dihydrogenase (DHODH) inhibitors
TW202332436A (zh) 治療用化合物
NZ729494A (en) Pyrazolothiazole compound and medicine comprising same
US20230151017A1 (en) Therapeutic agents targeting gpr35
US20250346605A1 (en) New derivatives for treating trpm3 mediated disorders
JP7680371B2 (ja) Ａｂｈｄ１２阻害剤並びにその作製及び使用方法
HK40059523A (en) Gpr35 modulators
CN121226261A (zh) 作为wrn抑制剂的含芳香环化合物及其应用
TWI910148B (zh) 芳基或雜芳基衍生物
WO2026041127A1 (zh) Nlrp3抑制剂及其制备方法和用途
EA048936B1 (ru) Модуляторы gpr35
HK40105573A (zh) Lpa受体拮抗剂及其用途
IL324265A (en) Cndp2 modulators and methods for their use
CN113015736A (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059523

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant